Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Undeclared APIs In ED Supplements From China Prompt FDA Warning

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The U.S. FDA warned consumers Dec. 28 about using erectile dysfunction dietary supplements produced in China because some products contained undeclared active pharmaceutical ingredients

You may also be interested in...



Singapore's S*BIO Moving JAK2 Inhibitor Into Phase II In Early 2010

S*BIO's collaboration with Onyx for two JAK2 inhibitors was one of the biggest biotech deals in Asia; data on one compound presented at ASH.

Singapore's S*BIO Moving JAK2 Inhibitor Into Phase II In Early 2010

S*BIO's collaboration with Onyx for two JAK2 inhibitors was one of the biggest biotech deals in Asia; data on one compound presented at ASH.

On To Phase II Trials For JAK2, Singapore's S*BIO Reports

PERTH, Australia - Singapore-based biotech S*BIO reported positive data on its Phase I trials for its Janus kinase 2 inhibitor SB1518 at the American Society of Hematology annual meeting in New Orleans Dec. 7

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel